Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q3 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $34K.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $8.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$34K-10.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Cost of Revenue vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.5% is the 4th highest of 7, against a peer median of -26.3%.
TRVI Competitors
Cost of Revenue for TRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$79.33M USD-6.2%+106.1%6.6%
LQDALiquidia CorporationLTM Jun 2026$33.93M USD+492.3%+66.7%7.5%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$21.55M USD-46.3%-55.7%19.6%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$1M USD+7.4%+307.8%5.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$646K USD-97.5%-82.7%0.9%
UPBUpstream Bio, Inc.LTM Mar 2026$49K USD——1.5%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$34K USD-10.5%——
VCREVicore Pharma Holding ABLTM Jun 2026SEK 0 SEK-100.0%—0.0%
TENXTenax Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding TRVI) —-26.3%+66.7%5.0%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development22.98M19.83M23.68M39.38M33.48M
Selling, General & Admin9.49M10.07M10.24M12.15M15.85M
Operating Expenses32.48M29.91M33.92M51.52M49.33M
Depreciation & Amortization50K43K123K147K144K
EBITDA(32.71M)(27.98M)(28.58M)(47.79M)(42.68M)
EBITDA Margin—————
Operating Income(32.48M)(29.91M)(33.92M)(51.52M)(49.33M)
Operating Margin—————
Interest Income10K1.74M4.75M3.6M6.54M
Interest Expense1.2M780K391K4K0
Other Income / Expenses(1.49M)719K4.83M3.58M6.51M
Income Before Tax(33.96M)(29.19M)(29.1M)(47.94M)(42.82M)
Pre-Tax Margin—————
Income Tax Expense(21K)(36K)(32K)(30K)(64K)
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Net Margin—————
EPS (Basic)(1.49)(0.45)(0.29)(0.47)(0.29)
EPS (Diluted)(1.49)(0.45)(0.29)(0.47)(0.29)
Weighted Avg Shares22.84M64.54M99.03M101.04M145.1M
Weighted Avg Shares (Diluted)22.84M64.54M99.03M101.04M145.1M

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.